Full Text View
Tabular View
No Study Results Posted
Related Studies
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
This study has been terminated.
( slow accrual )
Study NCT00573404   Information provided by Vanderbilt-Ingram Cancer Center

First Received on December 13, 2007.   Last Updated on November 12, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastrointestinal Stromal Tumor
Additional conditions recognized in this trial
Gastrointestinal Stromal Tumors
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Site
Interventions listed in this trial
imatinib mesylate
sunitinib malate
pharmacological study
Additional drug interventions recognized in this trial
Imatinib
Sunitinib
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services